Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow GILEAD SCIENCES, INC.

Get SEC filing alerts via email and in your feed for GILEAD SCIENCES, INC.

GILD

GILEAD SCIENCES, INC.

About GILEAD SCIENCES, INC.

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for unmet medical needs. Its core areas include virology, oncology, and inflammation, with key products for HIV, hepatitis, COVID-19, and cancer. Operating globally, Gilead emphasizes first-in-class therapies, strategic collaborations, and a strong patent portfolio to maintain competitive advantage and improve patient outcomes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from GILEAD SCIENCES, INC.

1
1
GILEAD SCIENCES, INC. Gilead Sciences Reports $6.96 Billion Revenue and $2.02 Billion Net Income in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
GILEAD SCIENCES, INC. Gilead Sciences Reports $29.4 Billion Revenue and $8.5 Billion Net Income for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
GILEAD SCIENCES, INC. Gilead Sciences Reports $7.77 Billion Revenue in Q3 2025, Net Income Rises to $3.05 Billion

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
GILEAD SCIENCES, INC. Gilead Sciences Reports $7.1 Billion Revenue in Q2 2025, Driven by HIV Product Sales

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
GILEAD SCIENCES, INC. Gilead Sciences Reports $6.67 Billion Revenue and $1.32 Billion Net Income in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
GILEAD SCIENCES, INC. Gilead Sciences Reports $28.8 Billion Revenue with 6% Growth, Net Income Drops 92%

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
GILEAD SCIENCES, INC. Gilead Sciences Reports Mixed Q3 Results with Increased Revenues and Declining Profitability

Via official filing (AI summary) | over 1 year ago | 0 comments